<DOC>
	<DOCNO>NCT00371566</DOCNO>
	<brief_summary>This study compare activity lapatinib versus placebo follow chemoradiation . This study design explore effect lapatinib monotherapy apoptosis/necrosis , pre-treatment post-treatment tumour tissue sample subject locally advanced squamous cell carcinoma head neck .</brief_summary>
	<brief_title>A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Willing able sign write informed consent . Histologically cytologically confirm diagnosis SCCHN . Stage III , IVA IVB disease eligible , receive chemoradiation therapy primary treatment ( total dose ≥ 65 Gy ) . Subjects distant metastasis ( stage IVC ) exclude . Willing able tumour biopsy take screen second tumour biopsy take lapatinib/placebo administration . Male female ≥18 year age . Criteria female subject female partner male subject : Nonchildbearing potential ( i.e. , woman function ovary current document tubal ligation hysterectomy , woman postmenopausal ) ; Childbearing potential ( i.e. , woman function ovary document impairment oviductal uterine function would cause sterility . ) This category include woman oligomenorrhoea ( severe ) , woman perimenopausal , young woman begin menstruate . These subject must negative serum pregnancy test screen agree one following : Complete abstinence intercourse 2 week prior administration first dose study medication 28 day final dose study medication ; Consistent correct use one follow acceptable method birth control : male partner sterile prior female subject 's entry study sole sexual partner female subject ; implant levonorgestrel ; injectable progestogen ; intrauterine device ( IUD ) document failure rate le 1 % per year ; oral contraceptive ( either combine progestogen ) ; barrier method , include diaphragm condom spermicide . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Subjects must adequate haematological , renal hepatic function . Calculated creatinine clearance ≥50 ml/min determine method Cockcroft Gault [ Cockcroft , 1976 ] EDTA method . Absolute neutrophil count ≥1,500/μl , platelets ≥100,000/μl . Haemoglobin ≥9gm/dL ( 5mmol/L ) . Aspartate ( AST ) alanine transaminase ( ALT ) less three time upper limit normal range ( ULN ) . Total bilirubin ≤2.0 mg/dL . Left ventricular ejection fraction ( LVEF ) within institutional normal range measure echocardiogram ( ECHO ) Multigated Acquisition ( MUGA ) scan . Able swallow tablet whole swallow suspension tablet dissolve water study inclusion . If necessary , suspension may administer via percutaneous endoscopic gastrostomy ( PEG ) , percutaneous jejunostomy tube ( JTube ) , nasogastric tube ( NG Dobhoff type tube ) . Life expectancy least 6 month judge investigator . Exclusion criterion : Subjects paranasal sinus , nasopharyngeal nasal cavity tumour ; Subjects receive prior systemic chemotherapy give curative intent ; Subjects receive prior radiotherapy ; Prior concurrent treatment tyrosine kinase inhibitor ; Use investigational agent within 30 day 5 halflives , whichever longer , precede first dose lapatinib ; Concurrent use CYP3A4 inducer inhibitor ; Subjects know history uncontrolled symptomatic angina , arrhythmia , congestive heart failure ; History another malignancy within last 5 year , exception completely resect basal squamous cell skin cancer , successfully treat situ carcinoma . History noninvasive lesion insitu carcinoma head neck successfully treat surgery , photodynamics laser , permit ; Distant metastases , ie Stage IVC ; Females males childbearing potential sexually active , agree practice effective method contraception . ( For example oral contraceptive , IUD diaphragm plus spermicide ) ; Pregnant lactating female ( female patient childbearing potential undertake pregnancy test screen study completion/withdrawal visit ) ; Malabsorption syndrome , disease significantly affect GI function , could affect absorption lapatinib ; History allergic reaction appropriate diuretic antiemetic ( e.g . 5HT3 antagonist ) administer platinumbased chemotherapy ; The investigator consider patient unfit study result medical interview , physical examination , screen investigation ; Subjects take prohibit medication ( See Section 8.2 ) Other Eligibility Criteria Considerations : To assess potential impact subject eligibility regard safety , investigator must refer follow document ( ) detail information regard warning , precaution , contraindication , adverse event , significant data pertain investigational product ( ) use study : investigator 's brochure IB IB supplement , expedite investigator safety report</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>lapatinib</keyword>
	<keyword>ErbB1/ErbB2 inhibitor</keyword>
	<keyword>apoptosis</keyword>
</DOC>